Company introduction – Cyclolab Cyclodextrin Research and Development Ltd
CycloLab Cyclodextrin Research and Development Ltd. is a private SME with the focus on cyclodextrin research and development for over 30 years. We are working in the fields of pharmaceutical, cosmetic and food industry, agrochemical, environmental and analytical applications of cyclodextrins.
CycloLab has four main activities:
1. We produce Sulfobutylether Beta-Cyclodextrin (SBECD, Dexolve™) in multiple ton scale annually under cGMP conditions based on an FDA-approved Drug Master File. This is a potent general solubilizer and stabilizer excipient, compatible with any kinds of administration forms.
2. CycloLab operates as a CRO for cyclodextrin related services including:
i) development of products (pharma, cosmetic, food, agricultural industries) – formulation development, optimization, characterization, in vitro bioequivalence studies, etc.
ii) offering custom synthesis of cyclodextrins, fine-tailored for certain guest molecules or purposes,
iii) performing (sub)pilot-scale cGMP compliant manufacturing of cyclodextrins to be used as APIs or excipients in clinical studies or cyclodextrin enabled formulations for the same purpose that are not available in suitable grades globally
iv) all analytical tasks related to the above, under GMP (method development,validation, stability studies for formulation ingredients (APIs, cyclodextrins) and final products as well. In this aspect, we are deeply engaged with Sugammadex as well.
3. CycloLab offers the widest variety of cyclodextrins in various grades (pharma, standard, fine chemical) in a web shop system for various purposes (research, analytics, cell cultures, formulation studies, etc). Besides "regular" derivatives, we always develop something new and special, like maltooligomers, polymers or fluorescent-tagged products. Within the product list, several Sugammadex related compounds are included.
4. As an R&D company, we develop next generation proprietary cyclodextrins and explore potential applications as well. These are focused in several areas as evaluating cyclodextrins as excipients in new areas like protein stabilization and non-viral gene delivery, fermentation and enzymatic processes, serum free culture media, creating selective and targeted drug delivery systems and evaluation of cyclodextrins as API candidates for CNS diseases, infections and other conditions.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance